Abogen Chemical Drops Gansu Haotian Acquisition Plans H1 Net Loss Narrows by 90 Percent

On the evening of July 29, Abogen Chemical announced it will officially halt its planned acquisition of shares in Gansu Haotian Technology after failing to reach consensus on key deal terms. Despite multiple rounds of negotiations and thorough due diligence, the two sides could not align the acquisition details with Abogen’s evolving business needs.

The company stated that the decision was made to protect shareholder interests and better allocate resources for core projects. In recent months, Abogen has ramped up investments in new production lines and R&D initiatives, responding to strong demand from major clients.

Abogen’s “2+X” strategy continues to advance, with its main business showing solid progress and a robust supply chain built around six core manufacturing bases. These facilities—including those in Taicang, Nantong, Yancheng, Lanzhou, Shangyu, and Malta—are driving transformation and innovation in both agricultural and pharmaceutical intermediates.

According to its half-year earnings forecast, Abogen expects a net loss of 5–10 million yuan for H1 2025, a sharp improvement from last year’s 52 million yuan deficit. The company anticipates a return to operating profit in Q2, reflecting steady execution of its annual plan and deepened client partnerships.